pISSN 2508-6235 eISSN 2508-7576

Download original image
Fig. 5. Categorical weight loss for semaglutide and placebo in Semaglutide Treatment Effect in People with obesity (STEP) trials 1–4. Note that in STEP 2, the achievement of higher categories of weight loss was less in the semaglutide 2.4 mg treated participants, compared to STEP 1 and STEP 3. Note the greater achievement in weight loss categories in the placebo group in STEP 3. In STEP 3 in the presence of a more intensive behavioral intervention resulted in greater efficacy in the placebo group but in the semaglutide treatment group the categorical weight losses were less than in STEP 1 and STEP 3. (A) STEP 1: adapted from Wilding et al. N Engl J Med 2021;384:989- 1002 with permission.20 (B) STEP 2: modified from Davies et al. Lancet 2021;397:971-84.21 (C) STEP 3: modified from Wadden et al. JAMA 2021;325:1403-13.22 (D) STEP 4: modified from Rubino D et al. JAMA 2021;325:1414-25.23
J Obes Metab Syndr 2021;30:196~208 https://doi.org/10.7570/jomes21033